A guide to finding out your breast cancer risk, and whether you should be tested for BRCA mutations. I like my boobs. They’re great. They look fine in a T-shirt, it feels good when they're touched, ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

Genetics is always changing. It seems as if every day there is a new article about a new study, and trying to navigate all of this information can be quite confusing. This past month, a new study was ...

HealthDay News — Only about one-third of women receive genetic counseling before they undergo testing for BRCA mutations, and patients who receive genetic counseling beforehand display better ...

The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 ...

Should screening for BRCA1/2 mutations be expanded to all women diagnosed with breast cancer? This is the recommendation put forth in recent guidelines from the American Society of Clinical Oncology ...

Please provide your email address to receive an email when new articles are posted on . BRCA testing guidelines rely on age and the types, aggressiveness and quantity of cancers in a family, but ...

Only 23.3% of ovarian cancer patients receive BRCA testing, leading to higher treatment costs and advanced therapy lines. Non-White and low-income patients face increased financial toxicity, ...

Gila Pfeffer is a humor writer who splits her time between NYC and London. The following is an adapted excerpt from her memoir, "Nearly Departed: Adventures in Loss, Cancer, and Other Inconveniences." ...

Update: Despite the U.S. Supreme Court ruling last year year, BRCA gene testing has continued to be an issue in the courts. But a patent infringement case between Myriad Genetics (Nasdaq: MYGN) and ...